The objective of our project panel is to identify gene expression biomarkers from patient blood samples that can predict patient responsiveness to the recommended treatment.
The aim of the project is to develop biomarkers and methods to support, rationalize and accelerate the discovery and development of novel drugs for the treatment of psychotic disorders.
Our aim was to develop the prototype of kits adaptable in tumour genetics based on epigenetic measurements. Within this project we could eventually patent a universal control system for immunoprecipitation that is a proprietary platform technology with a wide application field including antibody drug development and antibody drug serum level monitoring.
The purpose of TargetAMD FP7 project is to develop such a transposon-based targeted ex-vivo method which aims the treatment of age related macular degeneration.
The objective of this project was develop a depletion kit prototype for diagnosis of diabetes complications.
The objective and the result of our experiments were the set up of a universal RT-QPCR method. The design software required for the method is provided open access.
The overall objective of the TRANSCOM and TRANSPATH FP7 projects is to establish the molecular nature of the role of the multifunctional enzymes transglutaminases in the pathogenesis of diseases which are known to involve their cross-linking activity.
|
Contacts
|